{"id":"bexarotene-targretin-lgd1069","safety":{"commonSideEffects":[{"rate":"75","effect":"Hypertriglyceridemia"},{"rate":"60","effect":"Hypercholesterolemia"},{"rate":"30","effect":"Headache"},{"rate":"25","effect":"Asthenia/fatigue"},{"rate":"20","effect":"Rash"},{"rate":"15","effect":"Hypothyroidism"},{"rate":"10","effect":"Leukopenia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Bexarotene binds to and activates retinoid X receptors, which are nuclear receptors involved in gene transcription. This activation induces cell cycle arrest and apoptosis in cutaneous T-cell lymphoma cells while also modulating immune responses. The drug's selective RXR agonism distinguishes it from pan-retinoid agonists and allows targeted effects on malignant lymphocytes.","oneSentence":"Bexarotene is a retinoid X receptor (RXR) agonist that selectively activates RXR to promote differentiation and apoptosis of malignant T cells.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:42:24.218Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Cutaneous T-cell lymphoma (mycosis fungoides)"},{"name":"Cutaneous manifestations of cutaneous T-cell lymphoma"}]},"trialDetails":[{"nctId":"NCT05296304","phase":"PHASE1","title":"A Study of Bexarotene Combined With Radiotherapy in People With Mycosis Fungoides","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2022-03-16","conditions":"Cutaneous T-cell Lymphoma","enrollment":20},{"nctId":"NCT04664829","phase":"PHASE1","title":"The Role of Bexarotene in Inducing Susceptibility to Chemotherapy in Metastatic TNBC","status":"COMPLETED","sponsor":"National Cancer Centre, Singapore","startDate":"2020-10-01","conditions":"Metastatic Triple-Negative Breast Carcinoma","enrollment":12},{"nctId":"NCT01116622","phase":"PHASE1","title":"Erlotinib (Tarceva) and Bexarotene (Targretin) Oral Capsules in Advanced Cancers of the Aerodigestive Tract","status":"COMPLETED","sponsor":"Dartmouth-Hitchcock Medical Center","startDate":"2003-04","conditions":"Advanced, Malignant Aerodigestive Tract Tumor (Lung, Head and Neck and Esophagus)","enrollment":24},{"nctId":"NCT03323658","phase":"PHASE1","title":"Bexarotene in Preventing Breast Cancer in Patients at High Risk for Breast Cancer","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2018-06-15","conditions":"Breast Atypical Ductal Hyperplasia, Breast Atypical Lobular Hyperplasia, Breast Ductal Carcinoma In Situ","enrollment":24},{"nctId":"NCT00411632","phase":"PHASE2","title":"BATTLE Program: Tarceva and Targretin in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2006-11-29","conditions":"Lung Cancer","enrollment":37},{"nctId":"NCT01134341","phase":"PHASE1","title":"Pralatrexate and Bexarotene in Patients With Relapsed or Refractory Cutaneous T-cell Lymphoma","status":"COMPLETED","sponsor":"Acrotech Biopharma Inc.","startDate":"2010-03","conditions":"Cutaneous T-cell Lymphoma, Mycosis Fungoides, Sezary Syndrome","enrollment":34},{"nctId":"NCT01007448","phase":"PHASE4","title":"Study Evaluating Two Dose Levels of Targretin Capsules in Participants With Refractory Cutaneous T-Cell Lymphoma (CTCL)","status":"COMPLETED","sponsor":"Bausch Health Americas, Inc.","startDate":"2010-01-06","conditions":"Refractory Cutaneous T-cell Lymphoma","enrollment":59},{"nctId":"NCT00153842","phase":"PHASE1, PHASE2","title":"A Study of Paclitaxel and Carboplatin in Combination With Bexarotene Oral Capsules in Patients With Advanced Lung Cancer","status":"TERMINATED","sponsor":"Dartmouth-Hitchcock Medical Center","startDate":"2001-08","conditions":"Carcinoma, Non-small-cell Lung","enrollment":33},{"nctId":"NCT00125372","phase":"NA","title":"Study of Tarceva and Targretin in Stage I-II Lung Cancer","status":"COMPLETED","sponsor":"Dartmouth-Hitchcock Medical Center","startDate":"2005-12","conditions":"Carcinoma, Non-small-cell Lung","enrollment":12},{"nctId":"NCT00125359","phase":"PHASE2","title":"Study of Tarceva and Targretin Oral Capsules in Patients With Advanced Lung Cancer","status":"COMPLETED","sponsor":"Konstantin Dragnev","startDate":"2005-08","conditions":"Carcinoma, Non-small-cell Lung","enrollment":42},{"nctId":"NCT00958074","phase":"PHASE2","title":"Vorinostat in Patients With Primary Cutaneous T-Cell Lymphoma","status":"TERMINATED","sponsor":"University of Washington","startDate":"2009-07","conditions":"Cutaneous T-cell Lymphoma Stage I, Cutaneous T-cell Lymphoma Stage II, Cutaneous T-cell Lymphoma Stage III","enrollment":11},{"nctId":"NCT00255801","phase":"PHASE2","title":"Liposomal Doxorubicin Followed By Bexarotene in Treating Patients With Cutaneous T-Cell Lymphoma","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2005-11","conditions":"Lymphoma","enrollment":37},{"nctId":"NCT00056056","phase":"PHASE3","title":"Ultraviolet Light Therapy Using Methoxsalen With or Without Bexarotene in Treating Patients With Mycosis Fungoides","status":"TERMINATED","sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","startDate":"2003-01","conditions":"Lymphoma","enrollment":93},{"nctId":"NCT01504490","phase":"PHASE1","title":"Phase I Study of CS-7017 and Bexarotene","status":"TERMINATED","sponsor":"Georgetown University","startDate":"2011-12","conditions":"Solid Tumors, Lymphoma, Multiple Myeloma","enrollment":9},{"nctId":"NCT00178841","phase":"PHASE2","title":"Combination Drug Study of Bexarotene and Rosiglitazone to Treat CTCL","status":"COMPLETED","sponsor":"Vanderbilt University","startDate":"2005-06","conditions":"Cutaneous T-cell Lymphoma, Mycosis Fungoides, Sezary Syndrome","enrollment":4},{"nctId":"NCT01782742","phase":"PHASE2","title":"Bexarotene Amyloid Treatment for Alzheimer's Disease","status":"COMPLETED","sponsor":"The Cleveland Clinic","startDate":"2013-02","conditions":"Alzheimer's Disease","enrollment":20},{"nctId":"NCT02061878","phase":"PHASE1","title":"A Study to Evaluate the Effect of Bexarotene on Beta-Amyloid and Apolipoprotein E Metabolism in Healthy Subjects","status":"COMPLETED","sponsor":"ReXceptor, Inc.","startDate":"2014-08","conditions":"Alzheimer's Disease","enrollment":12},{"nctId":"NCT00127101","phase":"PHASE1","title":"An Investigational Study of a Histone Deacetylase (HDAC) Inhibitor Plus Targretin in Cutaneous T-Cell Lymphoma Patients (0683-016)(TERMINATED)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2005-09","conditions":"Lymphoma","enrollment":23},{"nctId":"NCT00660231","phase":"PHASE2","title":"Gemcitabine and Bexarotene in Treating Patients With Progressive or Refractory Stage IB, Stage II, Stage III, or Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma","status":"COMPLETED","sponsor":"University College, London","startDate":"2008-03","conditions":"Lymphoma","enrollment":36},{"nctId":"NCT01001143","phase":"PHASE1","title":"Intravenous (IV) Decitabine and Oral Bexarotene for Acute Myelogenous Leukemia (AML)","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2010-05","conditions":"Leukemia, Myeloid, Acute","enrollment":19},{"nctId":"NCT00718770","phase":"EARLY_PHASE1","title":"A Pilot Clinical Trial for Poorly Differentiated Thyroid Cancer - Correlation to Retinoid and Peroxisome-proliferator-activated Receptor (PPARy) Expression","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2008-11","conditions":"Thyroid Cancer","enrollment":10},{"nctId":"NCT00514293","phase":"PHASE2","title":"Bexarotene, Tretinoin, and Combination Chemotherapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer","status":"UNKNOWN","sponsor":"Raghu Nandan, M.D., Inc","startDate":"2007-01","conditions":"Lung Cancer","enrollment":39},{"nctId":"NCT00030589","phase":"PHASE2","title":"Chemotherapy and Photodynamic Therapy in Treating Patients With Cutaneous T-Cell Lymphoma","status":"UNKNOWN","sponsor":"Millennix","startDate":"2001-02","conditions":"Lymphoma","enrollment":""},{"nctId":"NCT00141947","phase":"PHASE3","title":"Bexarotene Treatment in Schizophrenia","status":"UNKNOWN","sponsor":"Beersheva Mental Health Center","startDate":"2005-09","conditions":"Schizophrenia","enrollment":15},{"nctId":"NCT00003752","phase":"PHASE2","title":"Bexarotene in Treating Patients With Metastatic Breast Cancer","status":"COMPLETED","sponsor":"Ligand Pharmaceuticals","startDate":"1998-10","conditions":"Breast Cancer","enrollment":180},{"nctId":"NCT00050973","phase":"PHASE3","title":"Evaluation of Efficacy, Safety and Tolerability of Targretin Capsules in Patients With Advanced or Metastatic Non-small Cell Lung Cancer","status":"COMPLETED","sponsor":"Eisai Inc.","startDate":"","conditions":"Non-small Cell Lung Cancer","enrollment":623},{"nctId":"NCT00030849","phase":"PHASE2","title":"Bexarotene and Interferon Alfa in Treating Patients With Cutaneous T-Cell Lymphoma","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2001-10","conditions":"Lymphoma","enrollment":""},{"nctId":"NCT00055991","phase":"PHASE1","title":"Bexarotene in Preventing Breast Cancer in Women at Genetic Risk","status":"COMPLETED","sponsor":"Baylor Breast Care Center","startDate":"2001-09","conditions":"Breast Cancer","enrollment":87},{"nctId":"NCT00063076","phase":"PHASE2, PHASE3","title":"Phase II Randomized Bilateral Comparison of Topical Targretin Gel 1% in Alopecia Areata","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2003-05","conditions":"Alopecia Areata","enrollment":46},{"nctId":"NCT00127881","phase":"PHASE3","title":"Study of Human Monoclonal Antibody to Treat Mycosis Fungoides and Sezary Syndrome","status":"TERMINATED","sponsor":"Emergent Product Development Seattle LLC","startDate":"2005-07","conditions":"Mycosis Fungoides, Sezary Syndrome","enrollment":76},{"nctId":"NCT00535574","phase":"PHASE3","title":"Bexarotene Augmentation of Antipsychotic Treatment for Chronic Schizophrenia","status":"COMPLETED","sponsor":"Beersheva Mental Health Center","startDate":"2008-11","conditions":"Schizophrenia","enrollment":90},{"nctId":"NCT00050960","phase":"PHASE3","title":"Evaluation of Efficacy, Safety and Tolerability of Targretin Capsules in Patients With Advanced or Metastatic Non-small Cell Lung Cancer","status":"COMPLETED","sponsor":"Eisai Inc.","startDate":"2002-05","conditions":"Non-small Cell Lung Cancer","enrollment":612},{"nctId":"NCT00151008","phase":"PHASE2","title":"Bexarotene With Narrow-Band UVB for Psoriasis","status":"COMPLETED","sponsor":"University of Medicine and Dentistry of New Jersey","startDate":"2003-11","conditions":"Psoriasis","enrollment":35},{"nctId":"NCT00002212","phase":"PHASE2","title":"A Study of Targretin Capsules in Patients With AIDS-Related Kaposi's Sarcoma","status":"COMPLETED","sponsor":"Ligand Pharmaceuticals","startDate":"","conditions":"Sarcoma, Kaposi, HIV Infections","enrollment":27}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Bexarotene (Targretin LGD1069)","genericName":"Bexarotene (Targretin LGD1069)","companyName":"Beersheva Mental Health Center","companyId":"beersheva-mental-health-center","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Bexarotene is a retinoid X receptor (RXR) agonist that selectively activates RXR to promote differentiation and apoptosis of malignant T cells. Used for Cutaneous T-cell lymphoma (mycosis fungoides), Cutaneous manifestations of cutaneous T-cell lymphoma.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}